In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates


Ataman M., Mataraci-Kara E., Ozbek-Celik B.

JOURNAL OF RESEARCH IN PHARMACY, vol.25, no.5, pp.549-553, 2021 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.29228/jrp.45
  • Journal Name: JOURNAL OF RESEARCH IN PHARMACY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.549-553
  • Keywords: Non-fermentative, tetracycline, antibacterial agent, resistant bacteria, MIC, ENTEROBACTERIACEAE, COLISTIN
  • Istanbul University Affiliated: Yes

Abstract

The antibacterial effectiveness of eravacycline was compared with various antibiotics used in Acinetobacter therapy against multidrug-resistant (MDR) Acinetobacter baumannii strains. Antibacterial susceptibility studiea was achieved by the broth microdilution method against 52 non-duplicate, A. baumanniii strains to eravacycline, tobramycin, levofloxacin, cefepime, meropenem, and colistin. Eravacycline presented greater action than the comparators of the other group, cefepime, colistin, levofloxacin, and tobramycin. While the MIC50/90 values of eravacycline were 8/16 mg/ L and those for tobramycin, levofloxacin, cefepime, meropenem, and colistin were found 256/>256, 64/ >256, 256/ >256, 128/>256, and 0.5/256 mg/L, respectively. As a result, the present study showed that eravacycline was a potent effective antibiotic against MDR A. baumannii. Eravacycline could be an effective new alternative for use in particular, for the treatment of this problematic organism.